← Back to All Filings

Viatris Director Reports RSU Vesting and New Equity Grant

Low SignificanceMarch 10, 2026 at 7:18:04 PM EDT

Viatris Inc

$VTRS4CIK: 0001792044

Subscribe to track VTRS

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

Viatris Director Reports RSU Vesting and New Equity Grant

Company: Viatris Inc (VTRS) Form: 4 | Filed: 2026-03-10 Significance: Low

Insider: CORNWELL W DON Title: N/A | Relationship: Director

Transaction: • Type: Grant/Exercise • Shares: 24,835 • Price: $0.00 • Value: $0.00 • Owned After: 112,044

Key Insight: Routine compensation event involving the vesting of RSUs and a new annual grant. No open market buying or selling occurred.

Market Context: Transaction represents negligible dilution (0.002% of outstanding shares) for this $17.19B market cap company.

View Full Filing

Comprehensive Analysis

SEC Filing Analysis: Viatris Inc (VTRS)

Executive Summary

  • Trading Significance: Low
  • Key Takeaway: Director W. Don Cornwell reported routine vesting of Restricted Stock Units (RSUs) and received a new annual equity grant.
  • Market Impact: Neutral - This is a standard compensation event with no open market activity.

Company Information

FieldValue
CompanyViatris Inc
Ticker SymbolVTRS
CIK0001792044
IndustryPharmaceutical Preparations

Insider Information

FieldValue
NameCORNWELL W DON
CIK0001174477
Title/PositionN/A
RelationshipDirector

Transaction Details

FieldValue
Form Type4
Transaction Date2026-03-06
Transaction CodeM (Exercise/Vesting)
Security TypeCommon Stock
Shares Involved24,835 (Acquired via Vesting)
Price Per Share$0.00
Total Value$0.00
Shares Owned After112,044
Ownership TypeDirect

Financial Impact Assessment

Transaction Materiality

MetricValue
Transaction Value$0.00 (Grant/Vest)
% of Market Cap0.00%
Shares Transacted24,835
% of Shares Outstanding0.002%
Post-Transaction Ownership112,044 shares (0.009% of outstanding)
Materiality AssessmentLow

Impact Evaluation

  • Market Cap Context: Viatris has a market capitalization of $17.19 billion. This administrative transaction has no economic impact on the company's valuation.
  • Ownership Concentration: The insider holds approximately 0.01% of the 1.15 billion shares outstanding, typical for a non-executive director.
  • Dilution Impact: The vesting of 24,835 shares and new grant of 15,890 shares represents nominal dilution (<0.01%) to existing shareholders.
  • Transaction Significance: The transaction falls well below the 0.1% threshold for significance.

Market Impact Analysis

Stock Impact Prediction

  • Direction: Neutral
  • Reasoning: This is a non-discretionary transaction related to compensation plans. It does not reflect insider sentiment regarding the stock's future performance.

Volume & Sentiment

  • Expected Volume Impact: None.
  • Sentiment Indicator: Neutral.

Additional Context

Transaction Notes

  • Timing: The transaction occurred on March 6, 2026, with the filing submitted on March 10, 2026.
  • Special Circumstances: The filing details the vesting of RSUs granted in previous years and the accrual of Dividend Equivalent Units (DEUs). A new grant of 15,890 RSUs was also reported, vesting in 2027.
Topics:#VTRS#Viatris#SECFiling#Form4#InsiderTrading#PharmaStocks#StockMarket#FinancialEducation

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.